Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

NCT06589440 is registered in ClinicalTrials.gov with Stingray Therapeutics as lead sponsor.

NCT NCT06589440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06589440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Lead sponsor
Stingray Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
November 20, 2024
Completion date
July 31, 2027
Enrollment
70 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

refractory metastatic microsatellite stable colorectal cancer (mss-crc)